BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 26607)

  • 21. Dopamine agonists in Parkinson's disease.
    Calne DB; Burton K; Beckman J; Martin WR
    Can J Neurol Sci; 1984 Feb; 11(1 Suppl):221-4. PubMed ID: 6231979
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dopamine agonists as primary treatment in Parkinson's disease.
    Rinne UK
    Adv Neurol; 1987; 45():519-23. PubMed ID: 3103394
    [No Abstract]   [Full Text] [Related]  

  • 23. DA agonists -- ergot derivatives: lisuride: management of Parkinson's disease.
    Mov Disord; 2002; 17 Suppl 4():S74-8. PubMed ID: 12211144
    [No Abstract]   [Full Text] [Related]  

  • 24. DA agonists -- ergot derivatives: pergolide: management of Parkinson's disease.
    Mov Disord; 2002; 17 Suppl 4():S79-82. PubMed ID: 12211145
    [No Abstract]   [Full Text] [Related]  

  • 25. Tyrosine hydroxylase cells appearing in the mouse striatum after dopamine denervation are likely to be projection neurones regulated by L-DOPA.
    Darmopil S; Muñetón-Gómez VC; de Ceballos ML; Bernson M; Moratalla R
    Eur J Neurosci; 2008 Feb; 27(3):580-92. PubMed ID: 18279311
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of (3H)-terguride and (3H)-spiperone binding to dopamine receptors in the rat striatum.
    Valchár M; Dobrovský K; Krejcí I; Dlabac A
    Act Nerv Super (Praha); 1989 Apr; 31(1):77-9. PubMed ID: 2675526
    [No Abstract]   [Full Text] [Related]  

  • 27. Changes of tyrosine hydroxylase in parkinsonian brains and in the brains of MPTP-treated mice.
    Nagatsu T
    Adv Neurol; 1990; 53():207-14. PubMed ID: 1978515
    [No Abstract]   [Full Text] [Related]  

  • 28. Studies with bromocriptine. Part 2. Double-blind comparison with levodopa in idiopathic parkinsonism.
    Kartzinel R; Shoulson I; Calne DB
    Neurology; 1976 Jun; 26(6 PT 1):511-3. PubMed ID: 778655
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dopamine receptor stimulating effects of chanoclavine analogues, tricyclic ergot alkaloids, in the brain.
    Watanabe H; Somei M; Sekihara S; Nakagawa K; Yamada F
    Jpn J Pharmacol; 1987 Dec; 45(4):501-6. PubMed ID: 3127619
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Dopaminergic ergot combinations. A new therapeutic principle].
    von Werder K
    MMW Munch Med Wochenschr; 1983 Jun; 125(23):489-91. PubMed ID: 6410211
    [No Abstract]   [Full Text] [Related]  

  • 31. Microdialysis study of the effects of the antiparkinsonian drug budipine on L-DOPA-induced release of dopamine and 5-hydroxytryptamine by rat substantia nigra and corpus striatum.
    Biggs CS; Starr MS
    Synapse; 1999 Oct; 34(1):36-46. PubMed ID: 10459170
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of the nigrostriatal dopaminergic neurons in mediating the effect of exogenous L-dopa in Parkinson's disease.
    Melamed E
    Mt Sinai J Med; 1988 Jan; 55(1):35-42. PubMed ID: 3279303
    [No Abstract]   [Full Text] [Related]  

  • 33. Brain enkephalin receptors in Parkinson's disease.
    Rinne UK; Rinne JK; Rinne JO; Laakso K; Tenovuo O; Lönnberg P; Koskinen V
    J Neural Transm Suppl; 1983; 19():163-71. PubMed ID: 6321647
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dopamine receptor stimulating agonists in the treatment of Parkinson's disease.
    Agid Y; Barroche G; Bonnet AM; Javoy-Agid F; Kato G; Lhermitte F; Pollak P; Signoret JL
    Biomedicine; 1979 Jun; 30(2):67-71. PubMed ID: 383169
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Considerations in the drug treatment of parkinsonism (author's transl)].
    Hungerbühler JP; Regli F
    Schweiz Rundsch Med Prax; 1978 Nov; 67(45):1648-57. PubMed ID: 30976
    [No Abstract]   [Full Text] [Related]  

  • 36. The interactions of bromocriptine and lergotrile with dopamine and alpha-adrenergic receptors.
    Lew JY; Hata F; Ohashi T; Goldstein M
    J Neural Transm; 1977; 41(2-3):109-21. PubMed ID: 21229
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dopamine denervation does not alter in vivo 3H-spiperone binding in rat striatum: implications for external imaging of dopamine receptors in Parkinson's disease.
    Bennett JP; Wooten GF
    Ann Neurol; 1986 Apr; 19(4):378-83. PubMed ID: 3707090
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Dopaminergic agonists in Parkinson disease].
    Dubois B; Agid Y
    Rev Prat; 1986 Jan; 36(5):207-14. PubMed ID: 3961400
    [No Abstract]   [Full Text] [Related]  

  • 39. Multiple receptors for dopamine.
    Kebabian JW; Calne DB
    Nature; 1979 Jan; 277(5692):93-6. PubMed ID: 215920
    [No Abstract]   [Full Text] [Related]  

  • 40. Interactions of exogenous L-dopa with nigrostriatal dopaminergic neurons in Parkinson's disease.
    Melamed E
    Adv Neurol; 1990; 53():61-6. PubMed ID: 2173376
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.